Summary
Global Markets Direct’s, ‘Cedar Pollen Allergy - Pipeline Review, H1 2016’, provides an overview of the Cedar Pollen Allergy pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Cedar Pollen Allergy
- The report reviews pipeline therapeutics for Cedar Pollen Allergy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cedar Pollen Allergy therapeutics and enlists all their major and minor projects
- The report assesses Cedar Pollen Allergy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cedar Pollen Allergy
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cedar Pollen Allergy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cedar Pollen Allergy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
ALK-Abello A/S
Anergis SA
Circassia Pharmaceuticals Plc
Immunomic Therapeutics, Inc.
Japan Tobacco Inc.
REGiMMUNE Corporation
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cedar Pollen Allergy Overview 6
Therapeutics Development 7
Pipeline Products for Cedar Pollen Allergy - Overview 7
Pipeline Products for Cedar Pollen Allergy - Comparative Analysis 8
Cedar Pollen Allergy - Therapeutics under Development by Companies 9
Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes 10
Cedar Pollen Allergy - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Cedar Pollen Allergy - Products under Development by Companies 14
Cedar Pollen Allergy - Products under Investigation by Universities/Institutes 15
Cedar Pollen Allergy - Companies Involved in Therapeutics Development 16
ALK-Abello A/S 16
Anergis SA 17
Circassia Pharmaceuticals Plc 18
Immunomic Therapeutics, Inc. 19
Japan Tobacco Inc. 20
REGiMMUNE Corporation 21
Cedar Pollen Allergy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AllerJ - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ASP-4070 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drugs for Cedar Pollen Allergy - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
JCC-LAMP-Vax - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
MC-LAMP-Vax - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
RGI-1001 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farinae) allergen vaccine - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TO-206 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Vaccine for Cedar Pollen Allergy - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaccine for Japanese Cedar Pollen Allergy - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cedar Pollen Allergy - Recent Pipeline Updates 42
Cedar Pollen Allergy - Dormant Projects 47
Cedar Pollen Allergy - Product Development Milestones 48
Featured News & Press Releases 48
Aug 07, 2015: ALK’s partner for Japan reports positive Phase II/III trial results for Japanese Cedar SLIT-tablet 48
Mar 09, 2015: Immunomic Therapeutics to Present at BIO-Europe Annual Conference 48
Feb 20, 2015: Immunomic Therapeutics to Present Data on Its Proprietary LAMP Vaccine Platform at 2015 American Academy of Allergy, Asthma and Immunology Meeting 48
Apr 24, 2013: Immunomic Therapeutics Announces Interim Data Analysis Of Phase I Study To Treat Japanese Red Cedar Allergy 49
Nov 08, 2012: Immunomic Therapeutics Doses First Patient In Phase I Clinical Trial Of JRC-LAMP-Vax Vaccine To Treat Japanese Red Cedar Allergy 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52
List of Tables
Number of Products under Development for Cedar Pollen Allergy, H1 2016 7
Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Cedar Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2016 16
Cedar Pollen Allergy - Pipeline by Anergis SA, H1 2016 17
Cedar Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 18
Cedar Pollen Allergy - Pipeline by Immunomic Therapeutics, Inc., H1 2016 19
Cedar Pollen Allergy - Pipeline by Japan Tobacco Inc., H1 2016 20
Cedar Pollen Allergy - Pipeline by REGiMMUNE Corporation, H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Assessment by Combination Products, H1 2016 23
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Cedar Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2016 42
Cedar Pollen Allergy - Dormant Projects, H1 2016 47
List of Figures
Number of Products under Development for Cedar Pollen Allergy, H1 2016 7
Number of Products under Development for Cedar Pollen Allergy - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Top 10 Molecule Types, H1 2016 27
